|
1
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Lowrance WT, Roth BJ, Kirkby E, Murad MH
and Cookson MS: Castration-resistant prostate cancer: AUA guideline
amendment 2015. J Urol. 195:1444–1452. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tannock IF, de Wit R, Berry WR, Horti J,
Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, et
al: Docetaxel plus prednisone or mitoxantrone plus prednisone for
advanced prostate cancer. N Engl J Med. 351:1502–1512. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Petrylak DP, Tangen CM, Hussain MH, Lara
PN Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M,
et al: Docetaxel and estramustine compared with mitoxantrone and
prednisone for advanced refractory prostate cancer. N Engl J Med.
351:1513–1520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Carroll PR, Parsons JK, Andriole G,
Bahnson RR, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein JI,
Etzioni RB, et al: NCCN guidelines insights: Prostate cancer early
detection, version 2.2016. J Natl Compr Canc Netw. 14:509–519.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi
H, Suga T, Utsugi T, Ohyama Y, Kurabayashi M, Kaname T, Kume E, et
al: Mutation of the mouse klotho gene leads to a syndrome
resembling ageing. Nature. 390:45–51. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ito S, Fujimori T, Hayashizaki Y and
Nabeshima Y: Identification of a novel mouse membrane-bound family
1 glycosidase-like protein, which carries an atypical active site
structure. Biochim Biophys Acta. 1576:341–345. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kurosu H and Kuro-O M: The Klotho gene
family as a regulator of endocrine fibroblast growth factors. Mol
Cell Endocrinol. 299:72–78. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kim J, Eskiocak U, Stadler G, Lou Z,
Kuro-o M, Shay JW and Wright WE: Short hairpin RNA screen indicates
that Klotho beta/FGF19 protein overcomes stasis in human colonic
epithelial cells. J Biol Chem. 286:43294–43300. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Tiong KH, Mah LY and Leong CO: Functional
roles of fibroblast growth factor receptors (FGFRs) signaling in
human cancers. Apoptosis. 18:1447–1468. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Schlessinger J: Common and distinct
elements in cellular signaling via EGF and FGF receptors. Science.
306:1506–1507. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyake M, Ishii M, Koyama N, Kawashima K,
Kodama T, Anai S, Fujimoto K, Hirao Y and Sugano K:
1-tert-butyl-3-[6-(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido
[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase
inhibitor of fibroblast growth factor receptor-3 (FGFR3), inhibits
cell proliferation of bladder cancer carrying the FGFR3 gene
mutation along with up-regulation of p27/Kip1 and G1/G0 arrest. J
Pharmacol Exp Ther. 332:795–802. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhou X and Wang X: Klotho: A novel
biomarker for cancer. J Cancer Res Clin Oncol. 141:961–969. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wolf I, Levanon-Cohen S, Bose S, Ligumsky
H, Sredni B, Kanety H, Kuro-o M, Karlan B, Kaufman B, Koeffler HP
and Rubinek T: Klotho: A tumor suppressor and a modulator of the
IGF-1 and FGF pathways in human breast cancer. Oncogene.
27:7094–7105. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen B, Wang X, Zhao W and Wu J: Klotho
inhibits growth and promotes apoptosis in human lung cancer cell
line A549. J Exp Clin Cancer Res. 29:992010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Doi S, Zou Y, Togao O, Pastor JV, John GB,
Wang L, Shiizaki K, Gotschall R, Schiavi S, Yorioka N, et al:
Klotho inhibits transforming growth factor-beta1 (TGF-beta1)
signaling and suppresses renal fibrosis and cancer metastasis in
mice. J Biol Chem. 286:8655–8665. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhu Y, Xu L, Zhang J, Xu W, Liu Y, Yin H,
Lv T, An H, Liu L, He H, et al: Klotho suppresses tumor progression
via inhibiting PI3K/Akt/GSK3β/Snail signaling in renal cell
carcinoma. Cancer Sci. 104:663–671. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Xie B, Zhou J, Yuan L, Ren F, Liu DC, Li Q
and Shu G: Epigenetic silencing of Klotho expression correlates
with poor prognosis of human hepatocellular carcinoma. Hum Pathol.
44:795–801. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Poh W, Wong W, Ong H, Aung MO, Lim SG,
Chua BT and Ho HK: Klotho-beta overexpression as a novel target for
suppressing proliferation and fibroblast growth factor receptor-4
signaling in hepatocellular carcinoma. Mol Cancer. 11:142012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Feng S, Dakhova O, Creighton CJ and
Ittmann M: Endocrine fibroblast growth factor FGF19 promotes
prostate cancer progression. Cancer Res. 73:2551–2562. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ye X, Guo Y, Zhang Q, Chen W, Hua X, Liu
W, Yang Y and Chen G: bKlotho suppresses tumor growth in
hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1
signaling pathway. PLoS One. 8:e556152013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hori S, Miyake M, Onishi S, Tatsumi Y,
Morizawa Y, Nakai Y, Anai S, Tanaka N and Fujimoto K: Clinical
significance of α- and β-Klotho in urothelial carcinoma of the
bladder. Oncol Rep. 36:2117–2125. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Hori S, Miyake M, Tatsumi Y, Morizawa Y,
Nakai Y, Onishi S, Onishi K, Iida K, Gotoh D, Tanaka N and Fujimoto
K: Gamma-Klotho exhibits multiple roles in tumor growth of human
bladder cancer. Oncotarget. 9:19508–19524. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Trošt N, Peña-Llopis S, Koirala S, Stojan
J, Potts PR, Fon Tacer K and Martinez ED: γKlotho is a novel marker
and cell survival factor in a subset of triple negative breast
cancers. Oncotarget. 7:2611–2628. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Abramovitz L, Rubinek T, Ligumsky H, Bose
S, Barshack I, Avivi C, Kaufman B and Wolf I: KL1 internal repeat
mediates klotho tumor suppressor activities and inhibits bFGF and
IGF-I signaling in pancreatic cancer. Clin Cancer Res.
17:4254–4266. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Fon Tacer K, Bookout AL, Ding X, Kurosu H,
John GB, Wang L, Goetz R, Mohammadi M, Kuro-o M, Mangelsdorf DJ and
Kliewer SA: Research resource: Comprehensive expression atlas of
the fibroblast growth factor system in adult mouse. Mol Endocrinol.
24:2050–2064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Nagamatsu H, Teishima J, Goto K, Shikuma
H, Kitano H, Shoji K, Inoue S and Matsubara A: FGF19 promotes
progression of prostate cancer. Prostate. 75:1092–1101. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Anai S, Goodison S, Shiverick K, Hirao Y,
Brown BD and Rosser CJ: Knock-down of Bcl-2 by antisense
oligodeoxynucleotides induces radiosensitization and inhibition of
angiogenesis in human PC-3 prostate tumor xenografts. Mol Cancer
Ther. 6:101–111. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ito T, Shimada Y, Kan T, David S, Cheng Y,
Mori Y, Agarwal R, Paun B, Jin Z, Olaru A, et al: Pituitary
tumor-transforming 1 increases cell motility and promotes lymph
node metastasis in esophageal squamous cell carcinoma. Cancer Res.
68:3214–3224. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li LT, Jiang G, Chen Q and Zheng JN: Ki67
is a promising molecular target in the diagnosis of cancer
(Review). Mol Med Rep. 11:1566–1572. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wang Y, Chen L, Huang G, He D, He J, Xu W,
Zou C, Zong F, Li Y, Chen B, et al: Klotho sensitizes human lung
cancer cell line to cisplatin via PI3k/Akt pathway. PLoS One.
8:e573912013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Gao L, Wang X, Tang Y, Huang S, Hu CA and
Teng Y: FGF19/FGFR4 signaling contributes to the resistance of
hepatocellular carcinoma to sorafenib. J Exp Clin Cancer Res.
36:82017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Cao J, Zhu X, Zhao X, Li XF and Xu R:
Neutrophil-to-lymphocyte ratio predicts PSA response and prognosis
in prostate cancer: A systematic review and meta-analysis. PLoS
One. 11:e01587702016. View Article : Google Scholar : PubMed/NCBI
|
